The k is a full audit the quarters are just reviews, so the two big areas which is published info is shareholder equity being positive and as I said in our last Q we are more then enough at any listing price, 2,3,4 bucks 13.5 mill plus, and assets under management which we are over just the same for qualifying, so if you look at the last k we were minus -43 million approx and assets didn’t meet the requirement, so it always a k to k comparison and that’s just a reality - that’s the rules, not our individual case everyone’s case from being deficient to positive in those two areas, the only way any exchange can confirm numbers is with a full audit not a review Q.
(0)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links